Grade @ or higher anorexia ( @ -LSB- @ % -RSB- vs three -LSB- @ % -RSB- ; p = @ ) and diarrhoea ( @ -LSB- @ % -RSB- vs seven -LSB- @ % -RSB- ; p = @ ) were significantly more common in patients given SOX plus bevacizumab than in those given mFOLFOX@ plus bevacizumab .